AAPL 165.84 0.5091% MSFT 400.96 0.461% GOOG 157.95 1.4321% GOOGL 156.28 1.4212% AMZN 177.23 1.4889% NVDA 795.18 4.3543% META 481.73 0.1372% TSLA 142.05 -3.4002% TSM 129.75 1.6053% LLY 731.33 0.6912% V 272.33 0.9452% AVGO 1224.46 1.6394% JPM 189.41 1.9429% UNH 491.23 -1.9755% NVO 125.26 2.0781% WMT 60.14 1.0247% LVMUY 168.89 0.4222% XOM 120.57 0.5756% LVMHF 851.89 0.4528% MA 456.75 0.2986%
Last update at 2024-04-22T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -66.14700M | -60.56100M | -59.17300M | -51.37300M | -48.43500M |
| Minority interest | - | - | - | - | - |
| Net income | -64.87500M | -58.11800M | -56.53700M | -48.67100M | -48.43500M |
| Selling general administrative | 16.55M | 15.39M | 13.54M | 14.73M | 15.72M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1.18M | 1.75M | 0.55M | 2.22M | 2.52M |
| Reconciled depreciation | 2.52M | 2.44M | 2.64M | 2.70M | 2.42M |
| Ebit | -67.41900M | -63.20800M | -63.10200M | -57.11100M | -53.65100M |
| Ebitda | -63.62500M | -60.76500M | -60.46600M | -54.40900M | -51.23000M |
| Depreciation and amortization | 3.79M | 2.44M | 2.64M | 2.70M | 2.42M |
| Non operating income net other | - | 0.21M | 1.30M | 3.06M | 2.84M |
| Operating income | -67.41900M | -60.76500M | -60.46600M | -54.40900M | -51.23000M |
| Other operating expenses | 68.60M | 62.52M | 61.01M | 56.63M | 53.75M |
| Interest expense | 0.00200M | 0.00200M | 0.00600M | 0.02M | 0.04M |
| Tax provision | - | - | - | - | - |
| Interest income | 1.27M | 0.21M | 1.30M | 3.06M | 2.84M |
| Net interest income | 1.26M | 0.21M | 1.30M | 3.04M | 2.80M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -1.27200M | -2.44300M | -2.63600M | -2.70200M | 2.84M |
| Total revenue | 1.18M | 1.75M | 0.55M | 2.22M | 2.52M |
| Total operating expenses | 68.60M | 62.52M | 61.01M | 56.63M | 53.75M |
| Cost of revenue | - | - | - | - | 0.00000M |
| Total other income expense net | 1.27M | 0.20M | 1.29M | 3.04M | 2.79M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -66.14700M | -60.56100M | -59.17300M | -51.37300M | -48.43500M |
| Net income applicable to common shares | -66.14700M | -60.56100M | -59.17300M | -51.37300M | -48.43500M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 110.86M | 174.74M | 143.84M | 188.57M | 140.34M |
| Intangible assets | - | - | 9.59M | 16.38M | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.17M | 0.31M | 0.25M | 0.65M | 0.39M |
| Total liab | 28.25M | 27.47M | 28.70M | 31.67M | 16.24M |
| Total stockholder equity | 82.61M | 147.27M | 115.14M | 156.91M | 124.10M |
| Deferred long term liab | - | 9.31M | 9.59M | 16.38M | 7.69M |
| Other current liab | 5.29M | 4.40M | 3.77M | 3.95M | 5.43M |
| Common stock | 0.07M | 0.07M | 0.04M | 0.03M | 0.03M |
| Capital stock | 0.07M | 0.07M | 0.04M | 0.03M | 0.03M |
| Retained earnings | -357.01900M | -290.87200M | -230.31100M | -171.13800M | -119.76500M |
| Other liab | - | - | 0.13M | - | 7.69M |
| Good will | - | - | - | - | - |
| Other assets | 9.40M | 10.41M | 10.69M | 17.54M | 1.16M |
| Cash | 15.86M | 16.44M | 32.51M | 26.18M | 11.25M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 12.12M | 10.08M | 8.30M | 8.86M | 8.34M |
| Current deferred revenue | 0.88M | 0.53M | - | 0.54M | 0.27M |
| Net debt | 4.44M | 4.16M | -9.70100M | -1.17000M | -10.77600M |
| Short term debt | 4.17M | 3.20M | 2.53M | 2.21M | 0.27M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 20.30M | 20.59M | 22.81M | 25.01M | 0.48M |
| Other stockholder equity | 439.72M | 438.11M | 345.39M | 327.90M | 243.90M |
| Property plant equipment | 21.68M | 9.09M | 26.30M | 30.28M | 14.84M |
| Total current assets | 79.78M | 136.63M | 100.44M | 127.07M | 122.73M |
| Long term investments | 0.00000M | 8.04M | 0.00000M | 7.50M | - |
| Net tangible assets | 82.61M | 147.27M | 115.14M | 156.91M | 124.10M |
| Short term investments | 61.77M | 112.15M | 67.94M | 93.39M | 111.48M |
| Net receivables | - | - | - | - | - |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 1.78M | 1.94M | 2.00M | 2.17M | 2.38M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.16100M | -0.04500M | 0.01M | 0.11M | -0.06500M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.07M | 0.04M | 0.03M | 0.03M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -290.87200M | -230.31100M | -171.13800M | -119.76500M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 9.40M | 20.98M | 23.03M | 48.48M | 2.77M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 31.08M | 38.11M | 43.40M | 61.50M | 17.61M |
| Capital lease obligations | 20.30M | 20.59M | 22.81M | 25.01M | 0.48M |
| Long term debt total | - | - | - | 0.00200M | 0.21M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 58.35M | -52.57400M | 32.48M | 12.05M | -81.54700M |
| Change to liabilities | 0.70M | 0.41M | -0.89300M | -0.93500M | -0.25700M |
| Total cashflows from investing activities | 58.35M | -53.25300M | 32.48M | 10.80M | -87.20100M |
| Net borrowings | -0.01300M | 0.04M | -0.20800M | -0.26600M | -0.42700M |
| Total cash from financing activities | -2.04000M | 89.38M | 13.39M | 79.60M | 82.48M |
| Change to operating activities | -0.32500M | -0.86900M | 12.26M | -30.36000M | 1.40M |
| Net income | -66.14700M | -60.56100M | -59.17300M | -51.37300M | -48.43500M |
| Change in cash | -0.57700M | -16.06900M | 6.32M | 14.93M | -47.18800M |
| Begin period cash flow | 17.54M | 33.60M | 27.28M | 12.35M | 59.54M |
| End period cash flow | 16.96M | 17.54M | 33.60M | 27.28M | 12.35M |
| Total cash from operating activities | -56.88800M | -52.19800M | -39.55300M | -75.46800M | -42.47000M |
| Issuance of capital stock | 0.29M | 89.09M | 13.54M | 57.00M | 82.67M |
| Depreciation | 2.52M | 2.44M | 2.64M | 2.70M | 2.42M |
| Other cashflows from investing activities | - | - | - | 12.05M | -81.54700M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | -2.51800M | 81.04M | 13.54M | 79.87M | 82.91M |
| Other cashflows from financing activities | 0.20M | 0.30M | 0.06M | 22.87M | 0.24M |
| Change to netincome | - | 3.36M | 5.62M | 4.13M | 4.33M |
| Capital expenditures | 0.73M | 0.68M | 0.40M | 1.25M | 5.65M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | 1.89M | 13.32M | -28.71400M | 0.88M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -16.06900M | 6.32M | 14.93M | -47.18800M |
| Change in working capital | 0.72M | 0.20M | 11.36M | -31.01900M | 0.62M |
| Stock based compensation | 3.64M | 3.36M | 3.91M | 4.13M | 4.32M |
| Other non cash items | 2.38M | 2.10M | 1.74M | 1.37M | -1.39300M |
| Free cash flow | -57.61600M | -52.87700M | -39.94800M | -76.71900M | -48.12400M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SYBX Synlogic Inc |
-0.03 1.60% | 1.84 | - | - | 42.57 | 0.77 | 25.88 | -0.32 |
| NVO Novo Nordisk A/S |
2.55 2.08% | 125.26 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
3.76 3.07% | 126.26 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.64 1.43% | 399.92 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
2.35 2.71% | 89.17 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
301 Binney Street, Cambridge, MA, United States, 02142
| Name | Title | Year Born |
|---|---|---|
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | Pres, CEO & Director | 1976 |
| Mr. Antoine Awad | Chief Operating Officer | 1980 |
| Dr. Timothy K. Lu M.D., Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1981 |
| Dr. James J. Collins Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1966 |
| Mr. Michael Jensen | Chief Financial Officer | NA |
| Dr. David L. Hava Ph.D. | Chief Scientific Officer | 1975 |
| Dr. Elizabeth Wolffe | Head of Investor Relations & Corp. Communications | NA |
| Mr. Brendan St. Amant | Gen. Counsel & Corp. Sec. | NA |
| Mr. Ajay Munshi | VP of Corp. Devel. | NA |
| Mr. Adam Thomas | Chief People Officer | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...